0001209191-23-056185.txt : 20231120
0001209191-23-056185.hdr.sgml : 20231120
20231120213140
ACCESSION NUMBER: 0001209191-23-056185
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231116
FILED AS OF DATE: 20231120
DATE AS OF CHANGE: 20231120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ENGLEMAN EDGAR
CENTRAL INDEX KEY: 0001227162
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39988
FILM NUMBER: 231424344
MAIL ADDRESS:
STREET 1: 575 HIGH STREET
STREET 2: STE 201
CITY: PALO ALTO
STATE: CA
ZIP: 94301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bolt Biotherapeutics, Inc.
CENTRAL INDEX KEY: 0001641281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472804636
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-665-9295
MAIL ADDRESS:
STREET 1: 900 CHESAPEAKE DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: Bolt Therapeutics, Inc.
DATE OF NAME CHANGE: 20150504
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-11-16
0
0001641281
Bolt Biotherapeutics, Inc.
BOLT
0001227162
ENGLEMAN EDGAR
C/O BOLT BIOTHERAPEUTICS, INC.
900 CHESAPEAKE DRIVE
REDWOOD CITY
CA
94063
1
0
0
0
0
Common Stock
2023-11-16
4
S
0
7531
0.96
D
1989685
I
By Vivo Capital Fund VIII, L.P.
Common Stock
2023-11-17
4
S
0
8211
0.93
D
1981474
I
By Vivo Capital Fund VIII, L.P.
Common Stock
2023-11-20
4
S
0
27465
0.92
D
1954009
I
By Vivo Capital Fund VIII, L.P.
Common Stock
2023-11-16
4
S
0
1040
0.96
D
274749
I
By Vivo Capital Surplus Fund VIII, L.P.
Common Stock
2023-11-17
4
S
0
1134
0.93
D
273615
I
By Vivo Capital Surplus Fund VIII, L.P.
Common Stock
2023-11-20
4
S
0
3792
0.92
D
269823
I
By Vivo Capital Surplus Fund VIII, L.P.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.95 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (4) to this Form 4.
The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.93 to $0.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (5) to this Form 4.
The price reported herein is a weighted average price. These shares were sold on the open market in multiple transactions at prices ranging from $0.92 to $0.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (6) to this Form 4.
The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. The Reporting Person is one of the voting members of Vivo Capital VIII, LLC and may be deemed to have shared voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein.
/s/ William P. Quinn, Attorney-in-Fact
2023-11-20